Group 1 - The core management team of BeiGene has undergone a significant adjustment, with Dr. Wang Lai appointed as President while retaining his role as Global Head of R&D, overseeing key functions such as R&D, business development, and alliance management [1] - Dr. Wu Xiaobin, who previously held the position of President, remains in his role as President and Chief Operating Officer, making BeiGene the first pharmaceutical company to establish a "dual president" position [1] - In August, BeiGene also experienced a major personnel change with the appointment of Sean Shan, former Senior Vice President at Takeda Pharmaceuticals, as General Manager for Greater China, Central Asia, and South Asia, reporting to Dr. Wu Xiaobin [1] Group 2 - BeiGene has shown strong growth as a leading innovative drug company, achieving total revenue of 17.518 billion yuan in the first half of the year, representing a year-on-year increase of 46.0% [2] - The net profit attributable to the parent company reached 450 million yuan, marking a turnaround from losses in the same period last year [2] - The management team is expected to drive further business upgrades, and the company will continue to provide updates on any new developments [2]

Group 1 - The company has entered a dual presidency phase with the appointment of Dr. Wang Lai as the new president, alongside the existing president, Dr. Wu Xiaobin [1][3] - Dr. Wang will oversee the company's research and development, business development, and alliance management functions [1] - Dr. Wu will continue in his role as president and COO, responsible for global commercialization, production, and supply chain operations [3] Group 2 - Dr. Wang is a key figure in the company, having led the development of the BTK inhibitor, Zebutinib, which is projected to generate $2.6 billion in sales in 2024, ranking 20th in global oncology drug sales [3] - The success of Zebutinib is attributed to both its therapeutic breakthroughs and effective commercialization strategies [3] - The collaboration between Dr. Wang's R&D team and Dr. Wu's commercialization team has been noted as highly effective [3]

Group 1 - The core point of the article is the appointment of Wang Lai as the new President and Global Head of R&D at BeiGene, effective January 1, 2026, with a significant compensation package [1] - Wang Lai will receive an annual salary of $750,000 (approximately 5.28 million RMB) and is eligible for an annual target bonus equivalent to 75% of his base salary [1] - BeiGene will grant Wang Lai a one-time equity incentive of $10 million in the form of restricted stock units [1] Group 2 - Prior to his appointment, Wang Lai served as the Global Head of R&D at BeiGene since April 2021 and has held various leadership roles in R&D since joining the company in 2011 [2] - Wang Lai has an impressive academic background, having obtained a Bachelor's degree from Fudan University and a Ph.D. from the University of Texas Health Science Center [2] - He was a key leader in the development of the important drug, Zebrutinib, and was encouraged by BeiGene's co-founder, Wang Xiaodong, to return to China to help establish the company [2]

Core Viewpoint - BeiGene announced that Wu Xiaobin remains in his position as President and Chief Operating Officer, while Wang Lai has been appointed as the new President and Global Head of R&D, effective immediately [1] Group 1 - Wu Xiaobin's role in the company has not changed, continuing as President and COO [1] - The board of BeiGene approved the appointment of Wang Lai as President and Global Head of R&D [1] - Wang Lai will oversee the company's research, business development, and management of business alliance relationships [1]

Group 1: Eli Lilly - Eli Lilly has submitted a new oral weight loss drug, orforglipron, for FDA approval, indicating a competitive edge in the weight loss medication market [1] - Participants switching from Novo Nordisk's Wegovy to orforglipron maintained most of their weight loss, with an average rebound of only 0.9 kg [1] Group 2: Fosun Pharma - Fosun Pharma's subsidiary has signed a collaboration agreement with Clavis Bio, which could yield up to $363 million in payments [2] - Clavis Bio will have exclusive global rights (excluding mainland China, Hong Kong, and Macau) for development, production, and commercialization of the selected targets [2] - Fosun Pharma will also gain a minority stake in a new project company established by Clavis Bio for this collaboration [2] Group 3: Baidu - Baidu has announced plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and competitiveness [3] - The issuance and listing are subject to shareholder approval and regulatory approvals, with specific details yet to be finalized [3] Group 4: BeiGene - BeiGene has appointed Dr. Wang Lai as the new President and Global Head of R&D, reflecting the company's commitment to innovation in drug development [4] - Dr. Wang has been with BeiGene since 2011 and has progressively taken on more responsibilities in R&D leadership [4] Group 5: Junshi Biosciences - Junshi Biosciences announced that major shareholder Shanghai Tanying plans to reduce its stake by up to 2%, equating to approximately 2,053,380 shares [5] - The reduction is scheduled between January 13, 2026, and April 10, 2026, despite the shareholder's long-term confidence in the company's prospects [5]

百济神州(06160)发布公告，2025年12月17日，经百济神州有限公司(以下简称"公司")董事会审议通过， 公司董事会同意聘任公司全球研发负责人汪来博士担任公司总裁，全球研发负责人。聘任生效后，汪来 博士担任公司总裁，全球研发负责人职务，负责管理公司研发、业务拓展以及业务联盟关系管理等职 能。 ...

Core Viewpoint - BeiGene has appointed Dr. Wang Lai as the new President and Global Head of R&D, effective December 17, 2025, following approval by the company's board of directors [1] Group 1 - The board of directors of BeiGene has approved the appointment of Dr. Wang Lai [1] - Dr. Wang Lai will be responsible for managing the company's R&D, business development, and alliance management functions [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 海外監管公告 本公告乃百濟神州有限公司（BeOne Medicines Ltd., 「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條作出。 茲載列本公司於上海證券交易所網站刊發的《百濟神州有限公司關於聘任公司高 級管理人員的公告》，僅供參閱。 承董事會命 百濟神州有限公司 主席 歐雷強先生 香港，2025年12月18日 於本公告日期，本公司董事會包括主席兼執行董事歐雷強先生、非執行董事王 曉東博士，以及獨立非執行董事Olivier Brandicourt博士、Margaret Han Dugan 博士、Michael Goller先生、Anthony C. Hooper先生、Ranjeev Krishana先生、 Alessandro Riva博士、Corazon (C ...

北京商报讯（记者 丁宁）12月18日晚间，百济神州（688235）发布公告称，12月17日，经公司董事会 审议通过，公司董事会同意聘任公司全球研发负责人汪来担任公司总裁，全球研发负责人。聘任生效 后，汪来担任公司总裁，全球研发负责人职务，负责管理公司研发、业务拓展以及业务联盟关系管理等 职能。 公告显示，汪来自2021年4月起担任百济神州全球研发负责人。在此之前，自2011年加入公司以来，他 担任过多个研发领导职务，职责逐渐扩大。加入公司之前，于2008年至2011年，汪来在位于美国德克萨 斯州达拉斯的生物技术公司Joyant Pharmaceuticals担任研究主管。汪来于1996年获得复旦大学理学学士 学位，于2001年获得德克萨斯大学圣安东尼奥健康科学中心博士学位。 ...

关于聘任公司高级管理人员的公告 A股代码：688235 A股简称：百济神州 公告编号：2025-042 港股代码：06160 港股简称：百济神州 美股代码：ONC 百济神州有限公司 2025 年 12 月 17 日，经百济神州有限公司（以下简称"公司"）董事 会审议通过，公司董事会同意聘任公司全球研发负责人汪来博士担任公 司总裁，全球研发负责人。聘任生效后，汪来博士担任公司总裁，全球 研发负责人职务，负责管理公司研发、业务拓展以及业务联盟关系管理 等职能。 特此公告。 百济神州有限公司董事会 附件：汪来博士的履历 汪来博士自 2021 年 4 月起担任公司全球研发负责人。在此之前，自 2011 年加入公司以来，他担任过多个研发领导职务，职责逐渐扩大。 加入公司之前，于 2008 年至 2011 年，汪来博士在位于美国德克萨斯 州达拉斯的生物技术公司 Joyant Pharmaceuticals 担任研究主管。汪来 博士于 1996 年获得复旦大学理学学士学位，于 2001 年获得德克萨斯 大学圣安东尼奥健康科学中心博士学位。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误 导性陈述或者重大遗漏，并 ...